This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Vertex Pharmaceuticals Inc (VRTX)

NASDAQ: Health Care

Company Income Statement
Dec 2015 Dec 2014 Dec 2013 Dec 2012
Sales 1.03B 580.41M 1.21B 1.53B
Cost of Sales 125.54M 60.99M 81.91M 241.69M
Gross Operating Profit 906.79M 519.43M 1.13B 1.29B
Selling, General, and Administrative Expenses 377.08M 305.41M 362.34M 436.80M
Research & Development 996.17M 855.51M 918.78M 806.18M
Operating Income before D & A (EBITDA) -466.46M -641.49M -151.06M 42.37M
Depreciation & Amortization n.a. 63.26M 48.37M 38.19M
Interest Income n.a. 0.00 0.00 1.94M
Other Income - Net -6.71M 30.40M -49.94M 0.00
Special Income / Charges 0.00 0.00 -663.50M 0.00
Total Income Before Interest Expenses (EBIT) -475.38M -725.27M -953.39M 4.27M
Interest Expense 84.21M 72.86M 22.73M 16.65M
Pre-Tax Income -559.58M -798.13M -976.12M -12.38M
Income Taxes 30.38M 6.96M -288.57M 38.75M
Minority Interest -31.85M -4.19M -242.52M 55.90M
Net Income From Continuing Operations -589.96M -741.83M -687.55M -51.13M
Net Income From Discontinued Operations 0.00 -912.00K 0.00 0.00
Net Income From Total Operations -589.96M -742.75M -687.55M -51.13M
Extraordinary Income/Losses 0.00 0.00 0.00 0.00
Income From Cum. Effect of Acct. Change 0.00 0.00 0.00 0.00
Income From Tax Loss Carryforward 0.00 0.00 0.00 0.00
Other Gains / Losses 0.00 0.00 0.00 0.00
Total Net Income -558.12M -738.55M -445.03M -107.03M
Normalized Income
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
-587.76M -690.91M 16.47M -49.29M
Preferred Dividends
Net Income Available To Common 0.00 -741.83M -687.55M -51.13M
Basic EPS from Continuing Ops. -2.31 -3.14 -1.98 -0.50
Basic EPS from Discontinued Ops. 0.00 0.00 0.00 0.00
Basic EPS from Total Operations -2.31 -3.14 -1.98 -0.50
Basic EPS from Extraordinary Inc. 0.00 0.00 0.00 0.00
Basic EPS from Cum Effect of Accounting Change 0.00 0.00 0.00 0.00
Basic EPS from Tax Loss Carryf'd. 0.00 0.00 0.00 0.00
Basic EPS from Other Gains (Losses) 0.00 0.00 0.00 0.00
Basic EPS, Total -2.31 -3.14 -1.98 -0.50
Basic Normalized Net Income/Share -2.30 -2.92 0.05 -0.49
EPS fr Continuing Ops. -2.31 -3.14 -1.98 -0.50
EPS fr Discontinued Ops 0.00 0.00 0.00 0.00
EPS fr Total Ops. -2.31 -3.14 -1.98 -0.50
EPS fr Extraord. Inc. 0.00 0.00 0.00 0.00
EPS fr Cum Effect of Accounting Change 0.00 0.00 0.00 0.00
EPS fr Tax Loss Carfd. 0.00 0.00 0.00 0.00
EPS fr Other Gains (L) 0.00 0.00 0.00 0.00
EPS, Total -2.31 -3.14 -1.98 -0.50
Diluted Normalized Net Inc/Shr
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
-2.30 -2.92 0.05 -0.49
Dividends Paid per Share 0.00 0.00 0.00 0.00
VRTX News

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free

VRTX Vertex Pharmaceuticals Inc

Chart of VRTX

Analysts Ratings for VRTX

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 9 7 7 7
Moderate Buy 1 1 1 1
Hold 5 7 7 7
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
GET VRTX ANALYST REPORT

VRTX Chatter

Top Rated Stocks Top Rated Funds Top Rated ETFs